UTH · Unknown
United Therapeutics Corp Del
34/100
Smart-money confidence1 of 3 sources positive
Below average interest
No standout activity across the feeds we track.
What this band has actually done: stocks scoring 25–45 beat the S&P 500 over the next three months 45.3% of the time, across 39,662 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this
Hedge funds
45
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Who's behind the signal
Every informed buyer we can see on UTH, across all three feeds.
Hedge funds · 9
Tudor Investment (Paul Tudor Jones)
New position
Baillie Gifford & Co
Increased +9%
Point72 (Steve Cohen)
Increased +35%
Millennium Management (Englander)
Increased +167%
Renaissance Technologies
Decreased −4%
Bridgewater Associates (Dalio)
Unchanged
+3 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
UNITED THERAPEUTICS CORP DEL isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
1
New positions
3
Increasing
3
Decreasing
2
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.0%
Position change
NEW
0.0% of Tudor Investment's portfolio
Trust weight: 1.4×
% of portfolio
0.2%
Position change
+9%
0.2% of Baillie Gifford & Co's portfolio
Trust weight: 1.1×
% of portfolio
0.2%
Position change
+35%
0.2% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.2%
Position change
+167%
0.2% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
1.3%
Position change
−4%
1.3% of Renaissance Technologies's portfolio
Trust weight: 1.3×
% of portfolio
0.2%
Position change
—
0.2% of Bridgewater Associates's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
—
0.1% of Gotham Asset Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−16%
0.1% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−34%
0.1% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to UNITED THERAPEUTICS CORP DEL
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell UNITED THERAPEUTICS CORP DEL or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订